Interesting - might be that with the extra funds registration (i.e. approval) for AML is achieved first in Europe ...
"and thirdly an AML study in the extra medullary form which is an extension of our Australian Study, taking it to Europe so that we can achieve registration for our drug both in Europe and later in the US"Would be very very interesting if registration can be achieved for Extramedullary AML (which is an FTO indication) based on early clinical data.
EM AML is a devastating disease - so difficult to treat that usually patients are excluded from clinical trials.
https://www.ema.europa.eu/en/human-regulatory/research-development/prime-priority-medicines
RAC media coverage, page-744
-
- There are more pages in this discussion • 1,542 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.055(3.31%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.68 | $1.61 | $271.5K | 166.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1996 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 1305 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |